Drug General Information
Drug ID	D08AAV
Former ID	DIB004590
Drug Name	AZD-3514
Indication	Hormone refractory prostate cancer [ICD9: 140-229, 185; ICD10:C61]		Phase 1	[523468]
Company	AstraZeneca plc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Androgen receptor	Target Info	Antagonist	[532431]
KEGG Pathway	Oocyte meiosis
	Pathways in cancer
	Prostate cancer
NetPath Pathway	EGFR1 Signaling Pathway
	AndrogenReceptor Signaling Pathway
	FSH Signaling Pathway
Pathway Interaction Database	Regulation of nuclear SMAD2/3 signaling
	Coregulation of Androgen receptor activity
	Regulation of Androgen receptor activity
	Nongenotropic Androgen signaling
	Regulation of nuclear beta catenin signaling and target gene transcription
	FOXA1 transcription factor network
	Notch-mediated HES/HEY network
Reactome	Nuclear Receptor transcription pathway
	Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
WikiPathways	SIDS Susceptibility Pathways
	Integrated Pancreatic Cancer Pathway
	Prostate Cancer
	Integrated Breast Cancer Pathway
	Nuclear Receptors
	Androgen receptor signaling pathway
References
Ref 523468	ClinicalTrials.gov (NCT01351688) An Open Label Prostate Cancer Study in Japanese Patients. U.S. National Institutes of Health.
Ref 532431	AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.